Literature DB >> 7181520

Outcome of maple syrup urine disease.

E R Naughten, J Jenkins, D E Francis, J V Leonard.   

Abstract

The outcome of 12 children with classical maple syrup urine disease is reviewed. All patients presented in the neonatal period at ages varying from 5 to 21 (median 8) days. The time taken to make the diagnosis ranged from 1 day to longer than 9 months (median 7 days). Each survived his initial illness but 3 died later after apparently mild infections. Three of the 12 patients had a spastic quadriplegia and 6 others abnormal neurological signs without clear cerebral palsy. The single most important factor determining the outcome appears to be the time taken to make the diagnosis after the first symptoms. Two patients were diagnosed within 24 hours of the first symptoms and one is of above average ability. The other is mildly retarded but control of the disease was poor in his first 4 years of life. Outcome is unpredictable if the delay is between 3 and 14 days. Two children are of normal ability but 6 others are retarded. A delay longer than 14 days is invariably associated with mental retardation and cerebral palsy. We conclude that early diagnosis is essential to improve the outcome of this condition.

Entities:  

Mesh:

Year:  1982        PMID: 7181520      PMCID: PMC1628082          DOI: 10.1136/adc.57.12.918

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  8 in total

1.  LATE MANIFESTING VARIANT OF BRANCHED-CHAIN KETOACIDURIA (MAPLE SYRUP URINE DISEASE).

Authors:  R KIIL; T ROKKONES
Journal:  Acta Paediatr       Date:  1964-07       Impact factor: 2.299

2.  Maple syrup urine disease; an inborn error of the metabolism of valine, leucine, and isoleucine associated with gross mental deficiency.

Authors:  D Y MACKENZIE; L I WOOLF
Journal:  Br Med J       Date:  1959-01-10

3.  A new syndrome: progressive familial infantile cerebral dysfunction associated with an unusual urinary substance.

Authors:  J H MENKES; P L HURST; J M CRAIG
Journal:  Pediatrics       Date:  1954-11       Impact factor: 7.124

4.  Maple syrup urine disease. Four years' experience with dietary treatment of a case.

Authors:  J P Dickinson; J B Holton; G M Lewis; J M Littlewood; A E Steel
Journal:  Acta Paediatr Scand       Date:  1969-07

5.  Plasma amino acid concentrations in newborn infants breast-fed ad libitum.

Authors:  F Pohlandt
Journal:  J Pediatr       Date:  1978-04       Impact factor: 4.406

6.  Intermittent branched-chain ketonuria. Variant of maple-syrup-urine disease.

Authors:  J Dancis; J Hutzler; T Rokkones
Journal:  N Engl J Med       Date:  1967-01-12       Impact factor: 91.245

7.  Newborn screening for maple syrup urine disease (branched-chain ketoaciduria).

Authors:  E W Naylor; R Guthrie
Journal:  Pediatrics       Date:  1978-02       Impact factor: 7.124

8.  Outcome of early and long-term management of classical maple syrup urine disease.

Authors:  C L Clow; T M Reade; C R Scriver
Journal:  Pediatrics       Date:  1981-12       Impact factor: 7.124

  8 in total
  16 in total

1.  Maple syrup urine disease: favourable effect of early diagnosis by newborn screening on the neonatal course of the disease.

Authors:  E Simon; R Fingerhut; J Baumkötter; V Konstantopoulou; R Ratschmann; U Wendel
Journal:  J Inherit Metab Dis       Date:  2006-08       Impact factor: 4.982

2.  Developmental profile of patients with maple syrup urine disease.

Authors:  A Nord; W J van Doorninck; C Greene
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

3.  Early diagnosis and dietetic management in newborn with maple syrup urine disease. Birth to six weeks.

Authors:  E R Naughten; I P Saul; G Roche; C Mullins
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

4.  The early detection and management of inborn errors presenting acutely in the neonatal period.

Authors:  J V Leonard
Journal:  Eur J Pediatr       Date:  1985-03       Impact factor: 3.183

5.  The management and long term outcome of organic acidaemias.

Authors:  J V Leonard; P Daish; E R Naughten; K Bartlett
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

6.  Neuropsychometric outcome predictors for adults with maple syrup urine disease.

Authors:  C le Roux; E Murphy; P Hallam; M Lilburn; D Orlowska; P Lee
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

7.  Synaptic plasma membrane Na(+), K (+)-ATPase activity is significantly reduced by the alpha-keto acids accumulating in maple syrup urine disease in rat cerebral cortex.

Authors:  André Wajner; Cristiane Bürger; Carlos Severo Dutra-Filho; Moacir Wajner; Angela Terezinha de Souza Wyse; Clóvis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2007-03       Impact factor: 3.584

8.  Ultrastructural findings in maple syrup urine disease in Poll Hereford calves.

Authors:  P A Harper; P J Healy; J A Dennis
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

9.  Hudson memorial lecture. Neonatal management of organic acidurias. Clinical update.

Authors:  J M Saudubray; H Ogier; C Charpentier; E Depondt; F X Coudé; A Munnich; G Mitchell; F Rey; J Rey; J Frézal
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

10.  Intellectual performance of children with maple syrup urine disease.

Authors:  C Hilliges; D Awiszus; U Wendel
Journal:  Eur J Pediatr       Date:  1993-02       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.